EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study

Alix Arnaud iD, Samantha Schilsky, Jackie Lucia iD, Marta Maia, Fernando Laredo, Ana Paula Marques, Hikaru Okada, Andrew W Roberts

Clinical and Applied Thrombosis/Hemostasis · 2024

DOI: 10.1177/10760296241241525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2024. Verfasst von Alix Arnaud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Boston, MA, USA. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Single-Domain Antibodies, Purpura, Thrombocytopenic, Idiopathic, Thrombosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

European real-world data indicate that front-line treatment with caplacizumab is associated with improved clinical outcomes compared with delayed caplacizumab treatment. The objective of the study was to describe the characteristics, treatment patterns, and outcomes in hospitalized patients with an immune-mediated thrombotic thrombocytopenic purpura (iTTP) episode treated with front-line versus delayed caplacizumab in the US. This retrospective cohort analysis of a US hospital database included adult patients (≥18 years) with an acute iTTP episode (a diagnosis of thrombotic microangiopathy and ≥1 therapeutic plasma exchange [TPE] procedure) from January 21, 2019, to February 28, 2021. Unadjusted baseline characteristics, treatment patterns, healthcare resource utilization, and costs were compared between patients who received front-line versus delayed (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicSingle-Domain AntibodiesPurpura, Thrombocytopenic, IdiopathicThrombosisAdultHumansRetrospective StudiesPlasma ExchangeADAMTS13 ProteinHospitals

Stichwörter der Autor:innen

caplacizumabhealthcare resource utilizationhospital costsimmune thrombotic thrombocytopenic purpurareal-world evidence

Substanzen

caplacizumabSingle-Domain AntibodiesADAMTS13 Protein

Autor:innen und Institutionen

  • Sanofi, Boston, MA, USA.
  • Aetion, Inc., New York, NY, USA.
  • Sanofi, Lisbon, Portugal.
  • Sanofi, São Paulo, Brazil.
  • Sanofi K.K., Tokyo, Japan.

ORCID-Profile: Alix Arnaud, Jackie Lucia

Förderung

  • Sanofi

Zitieren

APA

Arnaud, A., Schilsky, S., Lucia, J., Maia, M., Laredo, F., Marques, A. P., Okada, H., & Roberts, A. W. (2024). Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296241241525

Vancouver

Arnaud A, Schilsky S, Lucia J, Maia M, Laredo F, Marques AP, et al. Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study. Clinical and Applied Thrombosis/Hemostasis. 2024. doi:10.1177/10760296241241525

BibTeX
@article{Arnaud2024,
  author = {Arnaud, Alix and Schilsky, Samantha and Lucia, Jackie and Maia, Marta and Laredo, Fernando and Marques, Ana Paula and Okada, Hikaru and Roberts, Andrew W},
  title = {Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2024},
  doi = {10.1177/10760296241241525}
}
Kostenlos starten →